systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-188Research ArticleСТАТЬИARTICLESАртериальная гипертония и применение нестероидных противовоспалительных препаратов: преимущество амлодипинаArterial hypertension and treatment of non steroidal anti-inflammatory drugs: advantage amlodipinЕжовМ. В.noemail@neicon.ruYezhovM. V.noemail@neicon.ruФГУ Российский кардиологический научно-производственный комплекс,
НИИ кардиологии им. А.Л. Мясникова, МоскваRussian Federation200923122022612326Copyright © Ежов М.В., Yezhov M.V., 20222022Ежов М.В., Yezhov M.V.Ежов М.В., Yezhov M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/188артериальная гипертензияамлодипиннестероидные противовоспалительные средстваarterial hypertensionamlodipinnonsteroidal anti-inflammatory drugsReferencesLiebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.Dahlof B, Sever P, Poulter NR, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Dahlof B, Sever P, Poulter NR, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Pitt B, Byington RP, Furberg CDet al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Pitt B, Byington RP, Furberg CDet al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Collins R, Peto R, MacMahon S, Hebert P et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.Collins R, Peto R, MacMahon S, Hebert P et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 2003; 5: 53-7.Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 2003; 5: 53-7.Johnson AC, Nguyen TV, Day RO. Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis. Ann Intern Med. 1994; 121: 289-300.Johnson AC, Nguyen TV, Day RO. Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis. Ann Intern Med. 1994; 121: 289-300.Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-84.Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-84.Nowak J, Wennmalm A. Influence of indomethacin and of prostaglandin E1 on total and regional blood flow in man. Acta Physiol Scand 1978; 102: 484-91.Nowak J, Wennmalm A. Influence of indomethacin and of prostaglandin E1 on total and regional blood flow in man. Acta Physiol Scand 1978; 102: 484-91.Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959-63.Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959-63.Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.Aw DJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6.Aw DJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6.Sandler DP, Burr FR, Weinberg CR. Non-steroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165-72.Sandler DP, Burr FR, Weinberg CR. Non-steroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165-72.Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983; 143: 1130-4.Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983; 143: 1130-4.Avanzini F, Palumbo G, Alli C et al. Effects of low dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens 2000; 13: 611-6.Avanzini F, Palumbo G, Alli C et al. Effects of low dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens 2000; 13: 611-6.Morgan T, Anderson A, Wilson D et al. Paradoxical effect of sodium restriction on blood pressure in people on slow channel calcium blocking drugs. Lancet 1986; 1: 793.Morgan T, Anderson A, Wilson D et al. Paradoxical effect of sodium restriction on blood pressure in people on slow channel calcium blocking drugs. Lancet 1986; 1: 793.Чазова И.Е., Ратова Л.Г. Антагонисты кальция в лечении артериальной гипертонии (исследование ЭТНА). Consilium Medicum 2005; 2: 25-7.Чазова И.Е., Ратова Л.Г. Антагонисты кальция в лечении артериальной гипертонии (исследование ЭТНА). Consilium Medicum 2005; 2: 25-7.Чазова И.Е., Ратова Л.Г. Эффективность антигипертензивной терапии у больных артериальной гипертонией в зависимости от риска сердечно-сосудистых осложнений. Кардиоваскул. терапия и профилактика. 2008; 7(2): 78-82.Чазова И.Е., Ратова Л.Г. Эффективность антигипертензивной терапии у больных артериальной гипертонией в зависимости от риска сердечно-сосудистых осложнений. Кардиоваскул. терапия и профилактика. 2008; 7(2): 78-82.
The authors declare that there are no conflicts of interest present.